RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer-Reference-Cited by-同舟云学术

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Published:2013-05-01 Issue:6 Volume:123 Page:2551-2563
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Serra Violeta,Eichhorn Pieter J.A.,García-García Celina,Ibrahim Yasir H.,Prudkin Ludmila,Sánchez Gertrudis,Rodríguez Olga,Antón Pilar,Parra Josep-Lluís,Marlow Sara,Scaltriti Maurizio,Pérez-Garcia José,Prat Aleix,Arribas Joaquín,Hahn William C.,Kim So Young,Baselga José

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference71 articles.

1. Targeting PI3K signalling in cancer: opportunities, challenges and limitations

2. Targeting the phosphoinositide 3-kinase pathway in cancer

3. Targeting the PI3K signaling pathway in cancer

4. Promoter methylation of thePTENgene is a common molecular change in breast cancer

5. Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Environment relevant exposure of perfluorooctanoic acid accelerates the growth of hepatocellular carcinoma cells through mammalian target of rapamycin (mTOR) signal pathway;Environmental Pollution;2024-01

2. Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022;Results in Chemistry;2024-01

3. RSK3 switches cell fate: from stress-induced senescence to malignant progression;Journal of Experimental & Clinical Cancer Research;2023-11-27

4. TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models;Molecular Cancer Therapeutics;2023-10-31

5. RSK4 confers paclitaxel resistance to ovarian cancer cells, which is resensitized by its inhibitor BI-D1870;Biochemical and Biophysical Research Communications;2023-10